Naloxegol Drug Utilization PASS

• Status: Completed
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway, Sweden, and Germany.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca; Kyowa Kirin Pharmaceutical Development Ltd
• Treatments: Naloxegol

Criteria

Inclusion Criteria:

1. The patient has at least 1 prescription of naloxegol in his/her medical record anytime during the study period.

2. The patient has at least 12 months of computerized records prior to the first prescription of naloxegol (index date)

Exclusion Criteria:

• No exclusion criteria will be applied